title: Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.
abstract: Chronic inflammation is a complex process that promotes carcinogenesis and tumor progression; however, the mechanisms by which specific inflammatory mediators contribute to tumor growth remain unclear. We and others recently demonstrated that the inflammatory mediators IL-1beta, IL-6, and PGE(2) induce accumulation of myeloid-derived suppressor cells (MDSC) in tumor-bearing individuals. MDSC impair tumor immunity and thereby facilitate carcinogenesis and tumor progression by inhibiting T and NK cell activation, and by polarizing immunity toward a tumor-promoting type 2 phenotype. We now show that this population of immature myeloid cells induced by a given tumor share a common phenotype regardless of their in vivo location (bone marrow, spleen, blood, or tumor site), and that Gr1(high)CD11b(high)F4/80(-)CD80(+)IL4Ralpha(+/-)Arginase(+) MDSC are induced by the proinflammatory proteins S100A8/A9. S100A8/A9 proteins bind to carboxylated N-glycans expressed on the receptor for advanced glycation end-products and other cell surface glycoprotein receptors on MDSC, signal through the NF-kappaB pathway, and promote MDSC migration. MDSC also synthesize and secrete S100A8/A9 proteins that accumulate in the serum of tumor-bearing mice, and in vivo blocking of S100A8/A9 binding to MDSC using an anti-carboxylated glycan Ab reduces MDSC levels in blood and secondary lymphoid organs in mice with metastatic disease. Therefore, the S100 family of inflammatory mediators serves as an autocrine feedback loop that sustains accumulation of MDSC. Since S100A8/A9 activation of MDSC is through the NF-kappaB signaling pathway, drugs that target this pathway may reduce MDSC levels and be useful therapeutic agents in conjunction with active immunotherapy in cancer patients.
authors.affiliation: Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250, USA.
authors.forename: Pratima
authors.initials: P
authors.lastname: Sinha
authors.forename: Chinonyerem
authors.initials: C
authors.lastname: Okoro
authors.forename: Dirk
authors.initials: D
authors.lastname: Foell
authors.forename: Hudson H
authors.initials: HH
authors.lastname: Freeze
authors.forename: Suzanne
authors.initials: S
authors.lastname: Ostrand-Rosenberg
authors.forename: Geetha
authors.initials: G
authors.lastname: Srikrishna
mesh_terms: D000818:Animals; D019046:Bone Marrow Neoplasms / Q000276:immunology / Q000473:pathology / Q000556:secondary; D040501:Calgranulin A / Q000096:biosynthesis / Q000097:blood / Q000502:physiology*; D040502:Calgranulin B / Q000096:biosynthesis / Q000097:blood / Q000502:physiology*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D002634:Chemotaxis, Leukocyte / Q000276:immunology*; D016130:Immunophenotyping; D018836:Inflammation Mediators / Q000097:blood / Q000502:physiology*; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D022423:Myeloid Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D013160:Splenic Neoplasms / Q000276:immunology / Q000473:pathology / Q000556:secondary
chemical_list: D040501:Calgranulin A; D040502:Calgranulin B; D018836:Inflammation Mediators
references.citation: J Exp Med. 2005 Oct 3;202(7):931-9
references.pmid: 16186186
references.citation: Cancer Res. 1998 Apr 1;58(7):1486-93
references.pmid: 9537252
references.citation: J Immunol. 2001 Jan 1;166(1):624-32
references.pmid: 11123346
references.citation: Lancet. 2001 Feb 17;357(9255):539-45
references.pmid: 11229684
references.citation: J Immunol. 2001 Apr 1;166(7):4678-88
references.pmid: 11254728
references.citation: Oncol Rep. 2001 May-Jun;8(3):591-6
references.pmid: 11295086
references.citation: Int J Biochem Cell Biol. 2001 Jul;33(7):637-68
references.pmid: 11390274
references.citation: J Biol Chem. 2002 Feb 1;277(5):3658-65
references.pmid: 11723110
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: J Neurochem. 2002 Mar;80(6):998-1008
references.pmid: 11953450
references.citation: Nature. 2002 Dec 19-26;420(6917):860-7
references.pmid: 12490959
references.citation: J Immunol. 2003 Jan 1;170(1):270-8
references.pmid: 12496409
references.citation: J Immunol. 2005 Oct 15;175(8):5412-22
references.pmid: 16210648
references.citation: Int J Oncol. 2005 Dec;27(6):1473-81
references.pmid: 16273201
references.citation: J Immunol. 2005 Dec 15;175(12):8200-8
references.pmid: 16339559
references.citation: Eur J Immunol. 2005 Dec;35(12):3533-44
references.pmid: 16331707
references.citation: J Immunol. 2006 Jan 1;176(1):284-90
references.pmid: 16365420
references.citation: Cancer Res. 2006 Jan 15;66(2):1123-31
references.pmid: 16424049
references.citation: Semin Cancer Biol. 2006 Feb;16(1):53-65
references.pmid: 16168663
references.citation: Cancer Res. 2006 Jul 1;66(13):6807-15
references.pmid: 16818658
references.citation: J Leukoc Biol. 2006 Oct;80(4):682-4
references.pmid: 16849612
references.citation: J Clin Invest. 2006 Oct;116(10):2777-90
references.pmid: 17016559
references.citation: Biochem Pharmacol. 2006 Nov 30;72(11):1622-31
references.pmid: 16846592
references.citation: J Leukoc Biol. 2007 Jan;81(1):28-37
references.pmid: 16943388
references.citation: Cancer Res. 2007 Jan 1;67(1):425; author reply 426
references.pmid: 17210725
references.citation: J Clin Invest. 2007 May;117(5):1155-66
references.pmid: 17476345
references.citation: J Clin Invest. 2007 May;117(5):1175-83
references.pmid: 17476347
references.citation: Cancer Res. 2007 May 1;67(9):4507-13
references.pmid: 17483367
references.citation: J Immunol. 2007 Jul 15;179(2):977-83
references.pmid: 17617589
references.citation: Nat Med. 2007 Sep;13(9):1042-9
references.pmid: 17767165
references.citation: Cancer Res. 2007 Oct 15;67(20):10019-26
references.pmid: 17942936
references.citation: FEBS Lett. 2007 Oct 30;581(26):5127-30
references.pmid: 17936757
references.citation: Blood. 2008 Jan 1;111(1):219-28
references.pmid: 17885078
references.citation: J Exp Med. 2008 Feb 18;205(2):275-85
references.pmid: 18208974
references.citation: Blood. 2008 Apr 15;111(8):4233-44
references.pmid: 18272812
references.citation: J Leukoc Biol. 2008 May;83(5):1136-44
references.pmid: 18285406
references.citation: Circ Res. 2008 May 23;102(10):1239-46
references.pmid: 18403730
references.citation: J Leukoc Biol. 2008 Jun;83(6):1484-92
references.pmid: 18339893
references.citation: Curr Cancer Drug Targets. 2008 Jun;8(4):243-52
references.pmid: 18537548
references.citation: Blood. 2008 Jun 15;111(12):5457-66
references.pmid: 18375791
references.citation: Carcinogenesis. 2008 Oct;29(10):2035-43
references.pmid: 18689872
references.citation: Cancer Immunol Immunother. 2009 Jan;58(1):49-59
references.pmid: 18446337
references.citation: Mol Cell Biol. 2003 Apr;23(7):2564-76
references.pmid: 12640137
references.citation: Trends Immunol. 2003 Apr;24(4):155-8
references.pmid: 12697438
references.citation: Blood. 2003 Jun 15;101(12):4878-86
references.pmid: 12586633
references.citation: Trends Immunol. 2003 Jun;24(6):302-6
references.pmid: 12810105
references.citation: J Leukoc Biol. 2003 Aug;74(2):186-96
references.pmid: 12885935
references.citation: Anticancer Res. 2003 May-Jun;23(3A):2043-51
references.pmid: 12894577
references.citation: J Immunol. 2003 Sep 1;171(5):2602-9
references.pmid: 12928412
references.citation: Trends Immunol. 2003 Dec;24(12):622-4
references.pmid: 14644132
references.citation: J Immunol. 2004 Jan 15;172(2):989-99
references.pmid: 14707072
references.citation: Clin Chim Acta. 2004 Jun;344(1-2):37-51
references.pmid: 15149869
references.citation: Cancer Cell. 2004 Sep;6(3):297-305
references.pmid: 15380520
references.citation: J Leukoc Biol. 1993 Jan;53(1):11-8
references.pmid: 7678846
references.citation: Mol Cell Biol. 2003 Feb;23(3):1034-43
references.pmid: 12529407
references.citation: J Immunol. 2003 Mar 15;170(6):3233-42
references.pmid: 12626582
references.citation: J Biol Chem. 1998 May 15;273(20):12427-35
references.pmid: 9575199
references.citation: Cell. 1999 Jun 25;97(7):889-901
references.pmid: 10399917
references.citation: Cancer Res. 2004 Dec 15;64(24):9018-26
references.pmid: 15604267
references.citation: J Immunol. 2005 Jan 15;174(2):636-45
references.pmid: 15634881
references.citation: Histopathology. 2005 Mar;46(3):256-69
references.pmid: 15720411
references.citation: Clin Cancer Res. 2005 Jul 15;11(14):5146-52
references.pmid: 16033829
references.citation: Clin Cancer Res. 2005 Sep 15;11(18):6713-21
references.pmid: 16166452
references.citation: Cancer Immunol Immunother. 2005 Nov;54(11):1137-42
references.pmid: 15877228
references.citation: Nat Rev Immunol. 2005 Oct;5(10):749-59
references.pmid: 16175180